Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Kerlo Research

Neither a doctor nor a teaching hospital

Research payments

$3,300,054

365 payments

Through program year 2025, Kerlo Research is reported as receiving $3,300,054 in research payments, across 365 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $226,075 31
2024 Research $1,568,745 85
2023 Research $767,129 116
2022 Research $597,244 109
2021 Research $122,156 16
2020 Research $10,795 4
2019 Research $7,910 4

Breakdown

Who paid Research payments · program years 2019–2025
  1. Braintree Laboratories, Inc. $1,010,435 20 payments
  2. Sun Pharmaceutical Industries Inc. $849,481 181 payments
  3. Chiesi USA, Inc. $770,022 63 payments
  4. Genentech, Inc. $344,908 38 payments
  5. GlaxoSmithKline, LLC. $54,669 12 payments
  6. Eli Lilly and Company $38,551 3 payments
  7. AstraZeneca UK Limited $38,508 2 payments
  8. Abbott Laboratories $31,700 9 payments
  9. Biohaven Pharmaceutical Holding Company Ltd. $26,016 2 payments
  10. Biohaven Pharmaceuticals, Inc. $25,686 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease $1,010,435 20 payments
  2. Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) $824,643 168 payments
  3. Roche Cancer Screening Collection Study $344,908 38 payments
  4. A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) $274,703 21 payments
  5. A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (Triton) $258,956 17 payments
  6. A 52-Week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500) Study to Evaluate the Efficacy and Safety of Two Doses of Chf6001 Dpi (Tanimilast) As Add-On to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (Pillar) (Pi $115,225 8 payments
  7. A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PILLAR) $81,189 10 payments
  8. Multicentre,Randomised,Double blind,Parallel Group,Placebo controlled,Time to first Asthma Exacerbation Phase tree Efficacy and Safety Study of Benralizumab in Paediatric Patients with Severe Eosinophilic Asthma Dominika $38,508 2 payments
  9. A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evalua $37,000 5 payments
  10. A Randomized Double-Blind Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder $27,702 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record